Praluent® (alirocumab) – New orphan indication
April 1, 2021 - The FDA approved Regeneron’s Praluent (alirocumab), as an adjunct to other low density lipoprotein cholesterol (LDL-C)-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C.
Download PDF
